0
0
In a significant breakthrough, Mayo Clinic scientists have identified the earliest cellular changes that may signal a heightened risk for ovarian cancer—offering hope for future early detection and prevention strategies for this often deadly disease.
Ovarian cancer is notoriously difficult to detect in its early stages, with about 75% of cases diagnosed only after the disease has already advanced to stage 3 or 4. This late detection is a major reason why ovarian cancer remains one of the most lethal gynecologic cancers.
The research was sparked by the case of a 22-year-old patient with two rare genetic conditions: a hereditary BRCA2 mutation, linked to hereditary breast and ovarian cancer (HBOC) syndrome, and a hereditary TP53 mutation, which causes Li-Fraumeni syndrome. Both mutations dramatically increase lifetime cancer risk. After being diagnosed with breast cancer and discovering a benign ovarian cyst, the patient opted for preventive surgery, including the removal of her ovaries and fallopian tubes.
Upon examining the removed tissue, Mayo Clinic researchers found early, hidden changes in the cells lining her fallopian tubes. Using advanced single-cell technologies, they observed that secretory cells—one of the two main types of epithelial cells in the fallopian tube—vastly outnumbered multiciliated cells. These secretory cells were also driving chronic inflammation, a known contributor to cancer development. Notably, the patient’s cells lacked progesterone receptor proteins, suggesting that oral contraceptives, which can reduce ovarian cancer risk in the general population, may not have been effective for her.
Dr. Nagarajan Kannan, co-lead author and director of the Stem Cell and Cancer Biology Laboratory at Mayo Clinic, emphasized the importance of these findings:
“Using cutting-edge, single-cell technologies, we traced how her epithelial cells were developmentally altered in ways that signaled a high risk for lethal ovarian cancer. These insights could pave the way for future strategies to detect the disease in its earliest, precancerous stages when prevention is still possible.”
To further this research, Mayo Clinic has established a living fallopian tube biobank, allowing scientists to study the earliest origins of ovarian cancer cell by cell. Organoids—miniature versions of fallopian tubes—are grown from patient specimens, enabling detailed study of inherited cancer mutations and their effects on tissue.
Dr. Jamie Bakkum-Gamez, the patient’s gynecologic oncology surgeon and co-lead author, highlighted the potential impact:
“Knowing how ovarian cancer begins and forms could not only lead to the development of earlier screening tools, but also more personalized risk-reduction strategies and improved guidance around the timing of preventive surgeries and fertility planning.”
The research team’s next steps involve using the biobank to pinpoint precisely when and where ovarian cancer originates in high-risk individuals. Their work lays the foundation for a new era of early detection and precision prevention, particularly for those with inherited cancer risks such as BRCA mutations.
Disclaimer:
This article summarizes recent scientific research and should not be interpreted as medical advice. While the findings are promising, they are based on a single patient case and ongoing research. For personal medical guidance or cancer risk assessment, consult a qualified healthcare provider.
